A. Sharma, X. Zhao, B. G. Hammill, A. F. Hernandez, G. C. Fonarow et al., Trends in noncardiovascular comorbidities among patients hospitalized for heart failure, Circ Heart Fail, vol.11, p.4646, 2018.

M. A. Cavender, P. G. Steg, S. C. Smith, K. Eagle, E. M. Ohman et al., Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the reduction of atherothrombosis for continued health (REACH) registry. Circulation, vol.132, pp.923-931, 2015.

C. W. Yancy, M. Jessup, B. Bozkurt, J. Butler, D. E. Casey et al., ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American college of cardiology foundation/American Heart Association task force on practice guidelines, Circulation, vol.128, pp.1810-1852, 2013.

A. Sharma, A. Green, A. Dunning, Y. Lokhnygina, S. M. Al-khatib et al., Causes of death in a contemporary cohort of patients with type 2 diabetes and atherosclerotic cardiovascular disease: insights from the TECOS trial, Diabetes Care, vol.40, pp.1763-1770, 2017.

W. B. White, S. Kupfer, F. Zannad, C. R. Mehta, C. A. Wilson et al., Cardiovascular mortality in patients with type 2 diabetes and recent acute coronary syndromes from the EXAMINE trial, Diabetes Care, vol.39, pp.1267-1273, 2016.

A. Rawshani, A. Rawshani, S. Franz-en, S. Franzen, N. Sattar et al., Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes, N Engl J Med, vol.379, pp.633-644, 2018.

P. D. Home, S. J. Pocock, H. Beck-nielsen, P. S. Curtis, R. Gomis et al., Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial, Lancet, vol.373, pp.2125-2135, 2009.

J. A. Dormandy, B. Charbonnel, D. Eckland, E. Erdmann, M. Massi-benedetti et al., Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial, Lancet, vol.366, pp.1279-1289, 2005.

A. Sharma, L. B. Cooper, M. Fiuzat, R. J. Mentz, J. P. Ferreira et al., Antihyperglycemic therapies to treat patients with heart failure and diabetes mellitus, JACC Heart Fail, vol.6, pp.813-822, 2018.

B. Zinman, C. Wanner, J. M. Lachin, D. Fitchett, E. Bluhmki et al., Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes, N Engl J Med, vol.373, pp.2117-2128, 2015.

D. Fitchett, B. Zinman, C. Wanner, J. M. Lachin, S. Hantel et al., Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME â trial, Eur Heart J, vol.37, pp.1526-1534, 2016.

B. Neal, V. Perkovic, K. W. Mahaffey, D. De-zeeuw, G. Fulcher et al., Canagliflozin and cardiovascular and renal events in type 2 diabetes, N Engl J Med, vol.377, pp.644-657, 2017.

S. D. Wiviott, I. Raz, M. P. Bonaca, O. Mosenzon, E. T. Kato et al., Dapagliflozin and cardiovascular outcomes in type 2 diabetes, N Engl J Med, vol.380, pp.1881-1882, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02543624

S. L. Chow, A. S. Maisel, I. Anand, B. Bozkurt, R. A. De-boer et al., Role of biomarkers for the prevention, assessment, and management of heart failure: a scientific statement from the, American Heart Association. Circulation, vol.135, pp.1054-1091, 2017.

W. B. White, G. L. Bakris, R. M. Bergenstal, C. P. Cannon, W. C. Cushman et al., EXamination of CArdiovascular OutcoMes with AlogliptIN versus Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome, Am Heart J, vol.162, pp.620-626, 2011.

W. B. White, C. P. Cannon, S. R. Heller, S. E. Nissen, R. M. Bergenstal et al., Alogliptin after acute coronary syndrome in patients with type 2 diabetes, N Engl J Med, vol.369, pp.1327-1335, 2013.

F. Zannad, C. P. Cannon, W. C. Cushman, G. L. Bakris, V. Menon et al., Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial, Lancet, vol.385, pp.2067-2076, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01745763

A. Sharma, C. P. Cannon, W. B. White, Y. Liu, G. L. Bakris et al., Early and chronic dipeptidyl-peptidase-IV inhibition and cardiovascular events in patients with type 2 diabetes mellitus after an acute coronary syndrome: a landmark analysis of the EXAMINE trial, J Am Heart Assoc, vol.7, 2018.

Y. C. Hwang, D. A. Morrow, C. P. Cannon, Y. Liu, R. Bergenstal et al., High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial, Diabetes Obes Metab, vol.20, pp.654-659, 2018.

P. Jarolim, W. B. White, C. P. Cannon, Q. Gao, and D. A. Morrow, Serial measurement of natriuretic peptides and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE trial, Diabetes Care, vol.41, pp.1510-1515, 2018.

M. A. Cavender, W. B. White, P. Jarolim, G. L. Bakris, W. C. Cushman et al., Serial measurement of highsensitivity troponin i and cardiovascular outcomes in patients with type 2 diabetes mellitus in the examine trial (examination of cardiovascular outcomes with alogliptin versus standard of care), Circulation, vol.135, pp.1911-1921, 2017.

B. A. Bergmark, C. P. Cannon, W. B. White, P. Jarolim, Y. Liu et al., Baseline adiponectin concentration and clinical outcomes among patients with diabetes and recent acute coronary syndrome in the EXAMINE trial, Diabetes Obes Metab, vol.19, pp.962-969, 2017.

P. Jarolim, High sensitivity cardiac troponin assays in the clinical laboratories, Clin Chem Lab Med, vol.53, pp.635-652, 2015.

T. Kempf, R. Horn-wichmann, G. Brabant, T. Peter, T. Allhoff et al., Circulating concentrations of growthdifferentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay, Clin Chem, vol.53, pp.284-291, 2007.

K. Thygesen, J. Mair, C. Mueller, K. Huber, M. Weber et al., Recommendations for the use of natriuretic peptides in acute cardiac care: a position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care, Eur Heart J, vol.33, pp.2001-2006, 2012.

S. J. Greene, R. J. Mentz, M. Fiuzat, J. Butler, S. D. Solomon et al., Reassessing the role of surrogate end points in drug development for heart failure, Circulation, vol.138, pp.1039-1053, 2018.

L. Shen, P. S. Jhund, U. M. Mogensen, L. Køber, B. Claggett et al., Re-examination of the best trial using composite outcomes, including emergency department visits, JACC Heart Fail, vol.5, pp.591-599, 2017.

M. Gori, D. K. Gupta, B. Claggett, E. Selvin, A. R. Folsom et al., Natriuretic peptide and high-sensitivity troponin for cardiovascular risk prediction in diabetes: the Atherosclerosis Risk in Communities (ARIC) study, Diabetes Care, vol.39, pp.677-685, 2016.

A. Sharma, S. R. Stevens, J. Lucas, M. Fiuzat, K. F. Adams et al., Utility of growth differentiation factor-15, a marker of oxidative stress and inflammation, in chronic heart failure: insights from the HF-ACTION study, JACC Heart Fail, vol.5, pp.724-734, 2017.

T. Kempf, M. Eden, J. Strelau, M. Naguib, C. Willenbockel et al., The transforming growth factor-b superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury, Circ Res, vol.98, pp.351-360, 2006.

R. D. Kociol, P. S. Pang, M. Gheorghiade, G. C. Fonarow, O. Connor et al., Troponin elevation in heart failure: prevalence, mechanisms, and clinical implications, J Am Coll Cardiol, vol.56, pp.1071-1078, 2010.

J. L. Januzzi, G. Filippatos, M. Nieminen, and M. Gheorghiade, Troponin elevation in patients with heart failure: on behalf of the third Universal Definition of Myocardial Infarction Global Task Force: Heart Failure Section, Eur Heart J, vol.33, pp.2265-2271, 2012.

U. C. Sharma, S. Pokharel, T. J. Van-brakel, J. H. Van-berlo, J. P. Cleutjens et al., Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction, Circulation, vol.110, pp.3121-3128, 2004.

D. J. Lok, S. I. Lok, P. W. Bruggink-andr-e-de-la-porte, E. Badings, E. Lipsic et al., Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure, Clin Res Cardiol, vol.102, pp.103-110, 2013.

, Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis, Lancet Diabetes Endocrinol, vol.4, pp.840-849, 2016.

C. B. Jong, H. Y. Li, S. L. Pan, M. Y. Hsieh, F. Y. Su et al., Relationship between body mass index, antidiabetic agents, and midterm mortality in patients with both type 2 diabetes mellitus and acute coronary syndrome, J Am Heart Assoc, vol.8, 2019.

P. P. Swoboda, A. K. Mcdiarmid, B. Erhayiem, D. P. Ripley, L. E. Dobson et al., Diabetes mellitus, microalbuminuria, and subclinical cardiac disease: identification and monitoring of individuals at risk of heart failure, J Am Heart Assoc, vol.6, p.5539, 2017.

L. Cooper, S. Lippmann, M. Greiner, A. Sharma, J. Kelly et al., Use of mineralocorticoid receptor antagonists in patients with heart failure and comorbid diabetes mellitus or chronic kidney disease, J Am Heart Assoc, vol.6, 2017.

R. Rørth, P. S. Jhund, U. M. Mogensen, S. L. Kristensen, M. C. Petrie et al., Risk of incident heart failure in patients with diabetes and asymptomatic left ventricular systolic dysfunction, Diabetes Care, vol.41, pp.1285-1291, 2018.

S. J. Greene, M. Vaduganathan, M. S. Khan, G. L. Bakris, M. R. Weir et al., Prevalent and incident heart failure in cardiovascular outcome trials of patients with type 2 diabetes, J Am Coll Cardiol, vol.71, pp.1379-1390, 2018.